Potential therapeutic targets in ARID1A -mutated cancers

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 11, 2015, Pages 1419-1422

  Bitler, Benjamin G ^a   Fatkhutdinov, Nail ^a,b   Zhang, Rugang ^a  

^a WISTAR INSTITUTE   (United States)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

ARID1A; EZH2; ovarian cancer; synthetic lethality

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; REGULATOR PROTEIN; SWITCH SUCROSE NON FERMENTABLE COMPLEX SUBUNIT ARID1A; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

CARCINOGENESIS; CHRONIC INFLAMMATION; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; GENE MUTATION; NEOPLASM; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS; PATHOLOGY;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT;

EID: 84946761485     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1062879     Document Type: Review

References (16)

1. Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 2013;45(6):592-601
2. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330(6001):228-31
3. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363(16):1532-43
4. Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 2015;21(3):231-8
5. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010;18(4):316-28
6. Fillmore CM, Xu C, Desai PT, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 2015;520(7546):239-42
7. Wang X, Sansam CG, Thom CS, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. Cancer Res 2009;69(20):8094-101
8. Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 2014;20(3):251-4
9. Oike T, Ogiwara H, Tominaga Y, et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res 2013;73(17):5508-18
10. Guan B, Wang TL, Shih Ie M. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 2011;71(21):6718-27
11. Meijer A, Kruyt FA, van der Zee AG, et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer 2013;109(10):2685-95
12. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303(5659):844-8
13. Wiegand KC, Hennessy BT, Leung S, et al. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 2014;14:120
14. Chandler RL, Damrauer JS, Raab JR, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat commun 2015;6:6118
15. Samartzis EP, Gutsche K, Dedes KJ, et al. Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition. Oncotarget 2014;5(14):5295-303
16. Park JH, Park EJ, Lee HS, et al. Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction. EMBO J 2006;25(17):3986-97